Institutional Investors Are Buying Inogen Inc (NASDAQ:INGN)

Inogen, Inc. (NASDAQ:INGN) Logo

Sentiment for Inogen Inc (NASDAQ:INGN)

Inogen Inc (NASDAQ:INGN) institutional sentiment increased to 1.25 in 2019 Q1. Its up 0.18, from 1.07 in 2018Q4. The ratio is positive, as 120 hedge funds started new or increased holdings, while 96 decreased and sold positions in Inogen Inc. The hedge funds in our partner’s database now hold: 22.35 million shares, down from 22.52 million shares in 2018Q4. Also, the number of hedge funds holding Inogen Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 41 Reduced: 55 Increased: 82 New Position: 38.

Inogen, Inc., a medical technology company, primarily develops, makes, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company has market cap of $1.38 billion. The companyÂ’s oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It has a 30.44 P/E ratio. It offers Inogen One systems, which are portable devices that concentrate the air around the patients to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories.

The stock increased 0.82% or $0.51 during the last trading session, reaching $62.68. About 240,715 shares traded. Inogen, Inc. (NASDAQ:INGN) has declined 58.70% since July 14, 2018 and is downtrending. It has underperformed by 63.13% the S&P500.

Analysts await Inogen, Inc. (NASDAQ:INGN) to report earnings on August, 6. They expect $0.50 EPS, down 23.08 % or $0.15 from last year’s $0.65 per share. INGN’s profit will be $10.97M for 31.34 P/E if the $0.50 EPS becomes a reality. After $0.24 actual EPS reported by Inogen, Inc. for the previous quarter, Wall Street now forecasts 108.33 % EPS growth.

Brown Capital Management Llc holds 2.61% of its portfolio in Inogen, Inc. for 2.71 million shares. Tirschwell & Loewy Inc owns 157,640 shares or 2.06% of their US portfolio. Moreover, Summit Creek Advisors Llc has 1.01% invested in the company for 59,280 shares. The Washington-based Zevenbergen Capital Investments Llc has invested 0.98% in the stock. Redwood Investments Llc, a Massachusetts-based fund reported 133,654 shares.

Inogen, Inc. (NASDAQ:INGN) Ratings Coverage

Ratings analysis reveals 100% of Inogen’s analysts are positive. Out of 2 Wall Street analysts rating Inogen, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $17500 while the high is $191. The stock’s average target of $181.50 is 189.57% above today’s ($62.68) share price. INGN was included in 7 notes of analysts from February 27, 2019. Piper Jaffray maintained the shares of INGN in report on Wednesday, February 27 with “Buy” rating. Needham maintained the stock with “Buy” rating in Wednesday, February 27 report. J.P. Morgan maintained the shares of INGN in report on Wednesday, February 27 with “Buy” rating.

More notable recent Inogen, Inc. (NASDAQ:INGN) news were published by: which released: “Janney jumps on board with Avid after Q4 beat in premarket analyst action – Seeking Alpha” on June 28, 2019, also with their article: “Bragar Eagel & Squire is Investigating Certain Officers and Directors of Inogen, Health Insurance Innovations, Amyris and Nutanix and Encourages Investors to Contact the Firm – GlobeNewswire” published on June 27, 2019, published: “A Peek Into The Markets: US Stock Futures Rise Ahead Of Economic Reports – Benzinga” on July 03, 2019. More interesting news about Inogen, Inc. (NASDAQ:INGN) were released by: and their article: “Needham doubles down on Inogen – Seeking Alpha” published on November 20, 2018 as well as‘s news article titled: “Inogen Q1 Earnings Preview – Seeking Alpha” with publication date: May 06, 2019.

Inogen, Inc. (NASDAQ:INGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.